At present, the COVID-19 pandemic is running rampant, having caused 2.18 million deaths.
Characterizing the global patent landscape of coronaviruses is essential not only for …

This paper examines the role of peer firm disclosures in sha** corporate research and
development (R&D) investments. Drawing on models of two‐stage R&D races, I hypothesize …

In 2007 the US Congress created the priority review voucher program to encourage the
development of drugs for neglected diseases. Under the program, the developer of a drug …

Introduction Neglected diseases are a significant global health challenge. Encouraging the
development of therapeutics and vaccines for these diseases would address an important …

Background In 2007, the priority review voucher (PRV) was implemented in the US to
incentivize research and development (R&D) for tropical diseases. The PRV is issued by the …

This paper focuses on the relationship between therapeutic value and different measures of
market rewards: the number of patents, price, market share, and revenues. Using an …

Many in the scientific community are concerned about the potential increase in prevalence
of insect-borne diseases such as Chagas disease, Chikungunya, dengue fever, malaria …

In anticipation of long-run competitive advantages, pharmaceutical companies often try to
enter new markets earlier than their competitors. It is questionable, however, whether this …

METHODS We evaluated uptake of 13 biosimilar products from June 3, 2015, to July 1,
2021, in the Medicare Fee-for-Service population. We included all first-and second …

VOI analyses assume that information has value as it can avoid the potential opportunity
loss due to implementing a sub-optimal treatment that would be considered optimal based …